These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25146403)

  • 1. [The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
    Guo X; Zhang Y; Xu G; Zhou X; Li L; Tang B
    Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):371-4. PubMed ID: 25146403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
    Steinberg BA; Hellkamp AS; Lokhnygina Y; Halperin JL; Breithardt G; Passman R; Hankey GJ; Patel MR; Becker RC; Singer DE; Hacke W; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
    Heart Rhythm; 2014 Jun; 11(6):925-32. PubMed ID: 24833235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey.
    Račkauskas G; Zabiela V; Marinskis G; Baranauskas A; Balkutė D; Alunderytė J; Puodžiūkynas A; Kazakevičius T; Kviesulaitis V; Aidietis A
    Medicina (Kaunas); 2017; 53(1):19-25. PubMed ID: 28284524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
    Guo Y; Wang H; Tian Y; Wang Y; Lip GYH
    Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
    Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
    Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W;
    Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
    Jones WS; Hellkamp AS; Halperin J; Piccini JP; Breithardt G; Singer DE; Fox KA; Hankey GJ; Mahaffey KW; Califf RM; Patel MR
    Eur Heart J; 2014 Jan; 35(4):242-9. PubMed ID: 24302273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland.
    Bednarski J; Cieszewska E; Strzelecki A; Filipiak KJ
    Kardiol Pol; 2013; 71(12):1260-5. PubMed ID: 23990227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
    Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA;
    Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.